ORLANDO, Fla., Aug. 22, 2006 (PRIMEZONE) -- RedChip Visibility, a division of RedChip Companies, announced today that they have initiated research on MedaSorb Technologies (OTCBB:MSBT).
Patrick Murphy, CFA, RedChip Research Analyst, wrote in the report:
"We believe it is reasonable to expect that MedaSorb will get its products to market in the time frame projected by management, and that the upside potential is more than sufficient to justify the many risks associated with an investment today. Assuming CytoSorbT (MedaSorb's primary product which is used in the treatment of the symptoms associated with sepsis, cardiopulmonary bypass surgery, organ donation transplantation, and drug overdoses.) makes it to market in 3 years, MedaSorb will be worth at least $375 million, 3 years from now."
To receive a complimentary copy of the RedChip Research Report for MSBT, please visit: http://www.redchip.com/visibility/about.asp?page=requestMSBT.
About RedChip Visibility(tm)
RedChip Visibility, a division of RedChip Companies Inc., writes fundamental research on small-cap companies. RedChip's success has been documented in Forbes, Barron's and the Wall Street Journal. RedChip Visibility(tm) provides small-cap companies access to both professional and individual small-cap investors by holding conferences throughout the United States, producing online corporate visibility programs, and writing company sponsored research.
The RedChip Companies Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2761
RedChip Visibility Research Disclosure
Any opinions expressed herein are subject to change. RedChip Companies Inc. is an affiliate of the Aurelius Consulting Group, Inc. MedaSorb Technologies, Inc. is a client of the Aurelius Consulting Group, Inc. and of RedChip Visibility, a division of RedChip Companies. MSBT paid RedChip Visibility $34,200 for the RedChip Visibility Research Program, which includes this report. RedChip Visibility, a division of RedChip Companies, Inc., and the Aurelius Consulting Group Inc., in a joint marketing agreement, have been contracted by MedaSorb Technologies, Inc. to increase investor awareness of MSBT to the small-cap equity community. These services may include investor conferences and digital and print distribution of MSBT investor related materials. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the Aurelius Consulting Group is an investor relations firm hired by the Company and receives a monthly fee of $9,500.